San Diego, CA -- (SBWIRE) -- 11/18/2015 -- An investigation for shareholders in EXACT Sciences Corporation shares over potential securities laws violations by EXACT Sciences in connection certain financial statements was announced.

Investors who purchased shares of EXACT Sciences Corporation (NASDAQ:EXAS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain statements by regarding EXACT Sciences' business, its prospects and its operations were materially false and misleading at the time they were made.

The U.S. Preventive Services Task Force ("USPSTF") issued a recommendation statements for colorectal cancer screening. The USPSTF included Cologuard in the draft guidelines as an alternative screening test, along with CT colonography. The draft guidelines recommend an "A" rating for colorectal cancer screening starting at age 50 and continuing until age 75. Screening for individuals age 75 through 85 is graded a "C." and The USPSTF recommended an "D" rating against screening for colorectal cancer in adults older than age 85 years.

On October 5, 2015, EXACT Sciences Corporation issued a statement following the U.S. USPSTF recommendation statement for colorectal cancer screening. Shares of EXACT Sciences Corporation (NASDAQ:EXAS) declined to as low as $6.79 per share on October 15, 2015.

Those who purchased shares of EXACT Sciences Corporation (NASDAQ:EXAS) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com